Gastroprotective and anti- Helicobacter pylori potential of herbal formula HZJW: safety and efficacy assessment

Jian-Hui Xie; Yun-Long Chen; Qing-He Wu; Jun Wu; Ji-Yan Su; Hong-Yin Cao; Yu-Cui Li; Yi-Sheng Li; Jin-Bin Liao; Xiao-Ping Lai; Ping Huang; Zi-Ren Su

doi:10.1186/1472-6882-13-119

BMC Complementary Medicine and Therapies

Table 3 Hematological values in rats orally treated with HZJW

From: Gastroprotective and anti-Helicobacter pylori potential of herbal formula HZJW: safety and efficacy assessment

Parameter unit sex			Hematological values
			0 mg/kg			1000 mg/kg			2500 mg/kg			5000 mg/kg
			13 wk	26 wk	Recovery	13 wk	26 wk	Recovery	13 wk	26 wk	Recovery	13wk	26 wk	Recovery
RBC	10¹²/L	Male	9.18 ± 0.31	8.86 ± 0.47	8.65 ± 0.32	9.04 ± 0.33	8.72 ± 0.40	8.83 ± 0.45	9.27 ± 0.29	8.21 ± 0.71	8.48 ± 0.35	8.99 ± 0.80	8.94 ± 0.50	9.07 ± 0.71
RBC	10¹²/L	Female	8.11 ± 0.28	7.90 ± 0.49	7.59 ± 0.55	8.30 ± 0.28	7.85 ± 0.69	8.01 ± 0.72	8.37 ± 0.79	7.84 ± 0.49	7.65 ± 0.41	8.58 ± 0.66	6.96 ± 1.47	7.90 ± 0.55
HGB	g/L	Male	174 ± 6	168 ± 6	170 ± 7	164 ± 7	166 ± 3	166 ± 3	171 ± 5	157 ± 11**	163 ± 5	168 ± 6	162 ± 6*	174 ± 8
HGB	g/L	Female	158 ± 2	162 ± 7	159 ± 10	163 ± 4	156 ± 12	167 ± 11	166 ± 10	155 ± 8	160 ± 10	166 ± 12	137 ± 29*	162 ± 4
HCT	%	Male	45.3 ± 1.3	43.7 ± 1.8	44.1 ± 1.8	43.9 ± 1.2	44.1 ± 1.1	43.3 ± 0.9	44.9 ± 1.3	42.2 ± 3.2	43.0 ± 1.4	44.4 ± 2.5	45.0 ± 2.4	46.5 ± 2.4
HCT	%	Female	40.8 ± 1.2	42.2 ± 2.3	40.7 ± 2.8	41.9 ± 1.2	41.6 ± 2.9	44.3 ± 3.1	42.2 ± 3.3	41.7 ± 2.4	41.0 ± 3.0	42.7 ± 2.6	37.8 ± 7.8	41.0 ± 1.7
MCV	fL	Male	49.3 ± 0.7	49.3 ± 1.2	51.0 ± 1.9	48.6 ± 1.7	50.6 ± 1.5	49.1 ± 1.6	48.4 ± 0.8	51.5 ± 1.8	50.7 ± 2.1	49.6 ± 3.3	50.3 ± 1.7	51.4 ± 1.5
MCV	fL	Female	50.3 ± 1.4	53.5 ± 1.3	53.7 ± 2.4	50.5 ± 1.7	53.0 ± 1.7	55.4 ± 1.5	50.4 ± 0.9	53.2 ± 1.7	53.6 ± 1.3	49.8 ± 1.1	54.4 ± 1.6	52.0 ± 1.7
MCH	pg	Male	19.0 ± 0.2	19.0 ± 0.6	19.7 ± 0.8	18.1 ± 0.5	19.1 ± 0.7	18.8 ± 0.9	18.4 ± 0.3	19.1 ± 0.9	19.3 ± 0.7	18.8 ± 1.4	18.1 ± 0.7*	19.2 ± 0.7
MCH	pg	Female	19.5 ± 0.7	20.6 ± 0.5	21.0 ± 0.8	19.7 ± 0.6	19.9 ± 0.7**	20.9 ± 0.8	19.9 ± 0.9	19.8 ± 0.6*	20.9 ± 0.5	19.4 ± 1.0	19.7 ± 0.9**	20.6 ± 0.9
MCHC	g/L	Male	385 ± 6	385 ± 7	386 ± 9	373 ± 9	376 ± 7*	383 ± 6	381 ± 4	371 ± 13*	380 ± 5	378 ± 10	361 ± 8*	374 ± 4*
MCHC	g/L	Female	387 ± 8	385 ± 6	391 ± 8	389 ± 3	376 ± 7*	378 ± 8	395 ± 12	373 ± 6*	389 ± 8	389 ± 17	362 ± 16*	395 ± 7
RDW	%	Male	13.6 ± 0.5	13.3 ± 0.5	13.5 ± 0.4	13.7 ± 0.2	13.3 ± 0.3	13.4 ± 0.3	13.5 ± 0.3	13.3 ± 0.5	13.4 ± 0.5	13.7 ± 0.3	13.4 ± 0.4	13.4 ± 0.7
RDW	%	Female	13.1 ± 0.3	12.8 ± 0.3	12.6 ± 0.3	13.0 ± 0.3	12.7 ± 0.3	12.5 ± 0.2	12.9 ± 0.3	12.6 ± 0.3	12.9 ± 0.2	12.8 ± 0.3	13.0 ± 0.4	12.6 ± 0.5
PLT	10⁹/L	Male	823 ± 87	906 ± 48	881 ± 107	797 ± 106	831 ± 71	906 ± 76	816 ± 39	819 ± 74	872 ± 42	795 ± 30	854 ± 69	940 ± 99
PLT	10⁹/L	Female	763 ± 55	756 ± 98	828 ± 60	859 ± 122	816 ± 62	936 ± 72	810 ± 45	792 ± 94	839 ± 91	848 ± 86	696 ± 271	865 ± 76
MPV	fL	Male	3.3 ± 0.4	3.7 ± 0.5	4.2 ± 0.7	3.3 ± 0.4	3.7 ± 0.4	4.2 ± 0.4	3.4 ± 0.4	3.9 ± 0.5	4.2 ± 0.4	3.5 ± 0.4	4.7 ± 0.5**	4.5 ± 0.6
MPV	fL	Female	3.4 ± 0.4	3.7 ± 0.5	4.1 ± 0.9	3.4 ± 0.4	4.0 ± 0.5	4.5 ± 0.2	3.5 ± 0.2	4.0 ± 0.6	4.4 ± 0.5	3.5 ± 0.4	4.6 ± 1.6	4.0 ± 0.2
PDW	%	Male	14.8 ± 0.5	14.4 ± 0.3	14.3 ± 0.6	15.3 ± 0.4	14.3 ± 0.6	13.9 ± 0.2	14.9 ± 0.5	14.3 ± 0.4	14.4 ± 0.5	15.2 ± 1.0	14.3 ± 0.4	14.6 ± 0.6
		Female	15.0 ± 0.5	14.7 ± 0.3	14.4 ± 0.6	14.9 ± 0.4	14.7 ± 0.4	15.1 ± 0.8	15.3 ± 0.8	14.6 ± 0.6	14.5 ± 0.7	15.3 ± 0.6	15.2 ± 1.9	14.1 ± 0.2
PT	s	Male	14.4 ± 1.8	19.0 ± 5.8	15.1 ± 0.9	18.1 ± 3.9	17.1 ± 4.4	15.1 ± 0.4	13.5 ± 0.4	15.2 ± 3.2	14.7 ± 0.4	15.2 ± 2.6	15.7 ± 3.4	14.5 ± 0.6
PT	s	Female	12.7 ± 0.6	13.4 ± 0.6	14.5 ± 0.5	12.4 ± 0.5	13.3 ± 0.5	14.4 ± 0.6	12.5 ± 0.3	13.7 ± 0.7	13.9 ± 0.5	12.5 ± 0.8	13.2 ± 1.0	14.1 ± 1.2
WBC	10⁹/L	Male	6.4 ± 0.4	4.6 ± 1.1	4.7 ± 1.6	8.5 ± 3.4	6.6 ± 1.2**	5.2 ± 2.1	10.5 ± 2.7**	6.1 ± 2.3	5.2 ± 0.9	11.9 ± 2.2*	6.5 ± 2.2*	5.5 ± 1.2
WBC	10⁹/L	Female	4.3 ± 1.2	3.1 ± 0.9	2.3 ± 0.6	6.0 ± 1.4	2.8 ± 0.8	2.4 ± 0.5	6.6 ± 2.5	3.1 ± 0.8	2.3 ± 0.6	6.9 ± 1.3	2.7 ± 1.2	2.7 ± 0.6
LYM	10⁹/L	Male	5.0 ± 0.4	3.9 ± 0.9	4.1 ± 1.3	6.7 ± 3.1	5.3 ± 0.9**	4.4 ± 1.8	7.6 ± 1.8*	4.8 ± 1.8	4.3 ± 0.6	9.3 ± 2.1**	4.9 ± 1.6	4.4 ± 0.9
LYM	10⁹/L	Female	3.5 ± 1.1	2.5 ± 0.7	1.9 ± 0.5	4.8 ± 0.8	2.2 ± 0.6	2.0 ± 0.4	5.3 ± 2.0	2.5 ± 0.6	1.9 ± 0.5	5.8 ± 1.4*	2.2 ± 1.0	2.2 ± 0.4
MON	10⁹/L	Male	0.1 ± 0.0	0.0 ± 0.1	0.0 ± 0.0	0.2 ± 0.1	0.1 ± 0.0	0.0 ± 0.0	0.2 ± 0.2	0.1 ± 0.1	0.0 ± 0.0	0.3 ± 0.1	0.1 ± 0.1	0.1 ± 0.0
MON	10⁹/L	Female	0.1 ± 0.1	0.1 ± 0.2	0.0 ± 0.0	0.1 ± 0.1	0.0 ± 0.0	0.0 ± 0.0	0.2 ± 0.1	0.0 ± 0.0	0.0 ± 0.0	0.2 ± 0.1	0.0 ± 0.0	0.0 ± 0.0
NE	10⁹/L	Male	1.2 ± 0.3	0.6 ± 0.2	0.6 ± 0.3	1.6 ± 0.5	1.2 ± 0.3**	0.8 ± 0.3	2.6 ± 0.8**	1.2 ± 0.5**	0.9 ± 0.2	2.2 ± 0.4**	1.5 ± 0.7**	1.1 ± 0.3
NE	10⁹/L	Female	0.7 ± 0.3	0.5 ± 0.2	0.3 ± 0.1	1.0 ± 0.7	0.6 ± 0.2	0.4 ± 0.1	1.1 ± 0.7	0.6 ± 0.1	0.4 ± 0.1	0.9 ± 0.3	0.5 ± 0.2	0.5 ± 0.1
EOS	10⁹/L	Male	0.0 ± 0.1	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.1 ± 0.1	0.0 ± 0.0	0.0 ± 0.0
EOS	10⁹/L	Female	0.0 ± 0.1	0.0 ± 0.0	0.0 ± 0.0	0.1 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.1	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.1	0.0 ± 0.0	0.0 ± 0.0
BAS	10⁹/L	Male	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0
BAS	10⁹/L	Female	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0
LYM	%	Male	77.7 ± 4.5	84.9 ± 0.9	86.7 ± 1.0	77.5 ± 5.2	80.7 ± 2.7**	83.4 ± 0.6**	72.8 ± 4.0	77.3 ± 2.4*	80.8 ± 1.8**	78.0 ± 4.7	75.9 ± 3.6**	79.0 ± 3.1**
LYM	%	Female	80.2 ± 6.1	80.0 ± 2.1	85.7 ± 0.7	80.3 ± 7.7	77.5 ± 3.7	83.9 ± 1.4*	79.8 ± 7.8	77.2 ± 2.3*	81.7 ± 2.6*	81.7 ± 6.2	78.9 ± 4.9	80.0 ± 2.0**
MON	%	Male	1.8 ± 0.3	1.1 ± 0.5	0.4 ± 0.1	1.9 ± 1.1	1.1 ± 0.4	0.5 ± 0.3	2.3 ± 0.7	1.4 ± 0.7	0.5 ± 0.2	2.7 ± 0.6	1.3 ± 0.5	1.1 ± 0.4
MON	%	Female	1.5 ± 0.5	2.4 ± 4.3	0.3 ± 0.2	2.6 ± 0.5	0.9 ± 0.4	0.3 ± 0.3	2.7 ± 1.1	1.2 ± 0.6	0.6 ± 0.4	3.0 ± 0.6	0.9 ± 0.6	0.5 ± 0.3
NE	%	Male	19.5 ± 4.8	13.4 ± 0.7	12.3 ± 1.1	20.0 ± 4.8	17.6 ± 3.0**	15.8 ± 0.6	24.5 ± 4.0	20.6 ± 2.6*	18.1 ± 1.7	18.7 ± 4.3	22.0 ± 3.6**	19.3 ± 3.4
NE	%	Female	16.8 ± 6.3	16.9 ± 4.4	13.8 ± 0.7	15.5 ± 7.9	20.7 ± 3.5	15.2 ± 1.5	16.6 ± 8.7	20.6 ± 2.7*	16.7 ± 2.6	14.2 ± 6.0	19.3 ± 4.1	18.7 ± 1.8
EOS	%	Male	0.7 ± 0.3	0.4 ± 0.3	0.4 ± 0.4 0	0.4 ± 0.3	0.3 ± 0.2	0.2 ± 0.1	0.3 ± 0.2	0.4 ± 0.3	0.4 ± 0.3	0.5 ± 0.2	0.5 ± 0.4	0.4 ± 0.2
EOS	%	Female	1.2 ± 0.2	0.5 ± 0.2	0.1 ± 0.1	1.0 ± 0.3	0.5 ± 0.2	0.5 ± 0.1	0.7 ± 0.5	0.7 ± 0.5	0.8 ± 0.6	0.8 ± 0.4	0.8 ± 0.5	0.5 ± 0.4
BAS	%	Male	0.3 ± 0.1	0.3 ± 0.2	0.2 ± 0.1	0.2 ± 0.2	0.3 ± 0.2	0.2 ± 0.1	0.1 ± 0.1	0.3 ± 0.2	0.1 ± 0.1	0.1 ± 0.1	0.3 ± 0.1	0.2 ± 0.0
BAS	%	Female	0.2 ± 0.2	0.3 ± 0.3	0.1 ± 0.1	0.5 ± 0.2	0.4 ± 0.3	0.1 ± 0.1	0.2 ± 0.3	0.2 ± 0.2	0.2 ± 0.3	0.3 ± 0.1	0.1 ± 0.2	0.2 ± 0.3
RET	‰	Male	11 ± 4	21 ± 5	10 ± 3	14 ± 6	18 ± 3	12 ± 2	16 ± 3*	18 ± 7	11 ± 4	14 ± 4	21 ± 5	11 ± 4
		Female	18 ± 4	21 ± 4	10 ± 3	19 ± 5	22 ± 4	17 ± 2	18 ± 4	18 ± 6	11 ± 3	14 ± 4	28 ± 7	10 ± 4

Note: Red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular HGB (MCH), mean corpuscular HGB concentration (MCHC), red cell distribution width (RDW), platelets (PLT), mean platelet volume (MPV), platelet distribution width (PDW), white blood cell (WBC) counts, reticulocytes (RET), neutrophils (NE), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), and basophils (BAS) prothrombin time (PT). Values are mean ± S.D. (n = 5 (4 weeks), 10 (26 weeks) or recovery (30 weeks)/sex/dose). * P < 0.05 & ** P < 0.01 compared with normal group.

Back to article page